Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Not on Peppol Peppol
Not registered in the Peppol network, mandatory for VAT-liable companies since 1 January 2026.
Financials
Financial year 2025
Applications biomédicales de la Biologie moléculaire from Sint-Jans-Molenbeek, company number BE0452972578, closed financial year 2025 with a result of € 470,198 after tax. For that financial year Applications biomédicales de la Biologie moléculaire recorded a gross margin of € -355,206 and equity of € 8.1 million. Compared with financial year 2024, the result moved from € 1.9 million to € 470,198. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 29, 2026.
€ 8.1 million
▲ 6% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 470,198
▼ 75% vs 2024
Profit after tax over the fiscal year.
€ 1.2 million
▼ 40% vs 2024
Cash and bank balances on the last day of the fiscal year.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € -173,317 | € -153,479 | € -3,830 | € -355,206 | ▼ € 351,376 |
| Profit after taxes | € -510,572 | € -274,397 | € 1,897,412 | € 470,198 | ▼ 75% |
| Equity | € 6,007,162 | € 5,732,765 | € 7,630,177 | € 8,100,375 | ▲ 6% |
| Total debts | € 15,303 | € 25,489 | € 28,540 | € 15,000 | ▼ 47% |
| Cash | € 55,827 | € 68,156 | € 2,030,448 | € 1,220,018 | ▼ 40% |
| Retained profit | € 6,007,162 | € 5,732,765 | € 7,630,177 | € 8,100,375 | ▲ 6% |
| Balance sheet total | € 6,022,464 | € 5,758,254 | € 7,658,717 | € 8,115,375 | ▲ 6% |
Key figures of Applications biomédicales de la Biologie moléculaire, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Applications biomédicales de la Biologie moléculaire?
What happened at Applications biomédicales de la Biologie moléculaire in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 470,198 (▼ 75% vs 2024). Source: NBB ↗
- Sabine COSTAGLIOTA stepped down as director. NBB
- Gilbert VASSART became a director. NBB
- Marc PARMENTIER became a director. NBB
- Sabine COSTAGLIOTA became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 510,572 loss in 2022 to € 470,198 profit in 2025.
Paid € 117,498 in corporate taxes since 2022.
Best year ever: 2024, with € 1.9 million profit.
Management
Behind Applications biomédicales de la Biologie moléculaire are Gilbert VASSART and Marc PARMENTIER. The same people are also behind Association Recherche biomédicale et Diagnostic. Marc PARMENTIER is also behind CHEMCOM.
Directors
According to the 2025 annual accounts
since 2023
since 2023
Sabine COSTAGLIOTA
Director
since 2023 · until 2026
Establishments
Establishment units
Physical locations of this company
Menuetstraat 31
1080 Sint-Jans-Molenbeek
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0452.972.578
- VAT number
- BE 0452.972.578
- Registered office
- Menuetstraat 31, 1080 Sint-Jans-Molenbeek
- Names & denominations
- Applications biomédicales de la Biologie moléculaire
- Enterprise type
- Rechtspersoon
- Legal form
- Non-profit association
- Legal situation
- Normale toestand
- Start date
- 31 May 1994
- Peppol
- Not registered